Bexxar
information and resources from the National Cancer Institute
NCI Thesaurus | Bexxar
(Other name for: iodine I 131 tositumomab)NCI Thesaurus | Bexxar
(Other name for: iodine I 131 tositumomab)
Tositumomab
Accel. Approv. (clinical benefit not established) Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy
Corixa Corporation Jun 27 2003
|
|
|
|
news articles
MDS Reports First Quarter 2006 Financial Results Mar 9, 2006
Canada NewsWire (press release), During the first quarter, we launched our new Equinox line of therapy system equipment for cancer treatment and BEXXAR(R), a product we manufacture for ...
MDS Reports First Quarter 2006 Financial Results Mar 9, 2006
Yahoo! News (press release) During the first quarter, we launched our new Equinox line of therapy system equipment for cancer treatment and BEXXAR®, a product we manufacture for ...
MDS Nordion Supports GlaxoSmithKline Inc. in Providing Innovative ... Nov 24, 2005
PR Newswire (press release), Bexxar(TM) therapy now available to Canadians with non-Hodgkin's lymphoma OTTAWA, Nov. 24 /PRNewswire-FirstCall/ - MDS Nordion, a ...
MDS Nordion Supports GlaxoSmithKline Inc. in Providing Innovative ... Nov 24, 2005
Biotech Intelligence (press release), ...(GSK), to supply and manufacture the radiopharmaceutical component, iodine-131 (I-131), used in Bexxar(TM) therapy. Made by GSK, Bexxar ...
MDS Reports Fourth Quarter and Fiscal 2005 Financial Results Dec 14, 2005
Yahoo! News (press release) TheraSphere®, our innovative treatment for liver cancer, became eligible for sale in Europe and Bexxar became available in Canada. ...
MDS Reports Fourth Quarter and Fiscal 2005 Financial Results Dec 14, 2005
Canada NewsWire (press release), TheraSphere(R), our innovative treatment for liver cancer, became eligible for sale in Europe and Bexxar became available in Canada. ...
Top cancer advances of 2005 Dec 5, 2005
Health24.com, Other notable advances included the success of the drug oxaliplatin in fighting colon cancer recurrence; the use of Rituxan and Bexxar combination therapy ...
|
|
